An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"
2020-07-04
عنوان الدراسة
An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"
داعم الدراسة
Novartis
دواء الدراسة
TKI258 / Sorafenib
رقم بروتوكول الدراسة
CTKI258A2302
حالة الدراسة
Completed
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.